Landeskrankenhaus Feldkirch Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2011
NCT01174979
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

empagliflozin (jardiance) (1 trial)

spadon (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Heart Failure (Phase 3)

Infarction (Phase 3)

Myocardial Infarction (Phase 3)

Tinnitus (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2